Cortria to use AAIPharma's controlled release oral drug delivery technology
Cortria has been granted the right to use AAIPharma's controlled release oral drug delivery technology known as ProCR with its TRIA-662 drug candidate.
Cortria has been granted the right to use AAIPharma's controlled release oral drug delivery technology known as ProCR with its TRIA-662 drug candidate.
Boston-based Cortria is a clinical-stage pharmaceutical company that develops medicines to fight cardiovascular disease.
AAIPharma is a global drug development company that provides services to the pharmaceutical, biotechnology, and medical device industries.
ProCR is a controlled-release technology developed for use with orally administered drug products. It consists of unique combinations of GRAS (generally recognised as safe) excipients, which when combined with an active pharmaceutical agent in a tablet or capsule, result in a near linear controlled release profile.
TRIA-662 is Cortria's lead drug candidate currently in Phase 2 clinical development for dyslipidemia, an atherogenic disorder characterised by abnormal fat levels in the bloodstream.
In preliminary human studies, TRIA-662 has shown the potential to provide the benefits for niacin therapy without causing skin flushing, a common, use-limiting side effect of niacin agents.
Further terms of the agreement were not disclosed.